NL6516326A - - Google Patents

Info

Publication number
NL6516326A
NL6516326A NL6516326A NL6516326A NL6516326A NL 6516326 A NL6516326 A NL 6516326A NL 6516326 A NL6516326 A NL 6516326A NL 6516326 A NL6516326 A NL 6516326A NL 6516326 A NL6516326 A NL 6516326A
Authority
NL
Netherlands
Application number
NL6516326A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of NL6516326A publication Critical patent/NL6516326A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/30—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Laminated Bodies (AREA)
  • Shaping By String And By Release Of Stress In Plastics And The Like (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
NL6516326A 1964-12-15 1965-12-15 NL6516326A (enExample)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH1616164A CH451945A (de) 1964-12-15 1964-12-15 Verfahren zur Herstellung von neuen N-Pyrimidylanthranilsäuren

Publications (1)

Publication Number Publication Date
NL6516326A true NL6516326A (enExample) 1966-06-16

Family

ID=4414930

Family Applications (2)

Application Number Title Priority Date Filing Date
NL129020D NL129020C (enExample) 1964-12-15
NL6516326A NL6516326A (enExample) 1964-12-15 1965-12-15

Family Applications Before (1)

Application Number Title Priority Date Filing Date
NL129020D NL129020C (enExample) 1964-12-15

Country Status (14)

Country Link
US (1) US3361749A (enExample)
AT (1) AT256854B (enExample)
BE (1) BE673707A (enExample)
BR (1) BR6575691D0 (enExample)
CH (1) CH451945A (enExample)
DE (1) DE1545978A1 (enExample)
DK (1) DK117835B (enExample)
ES (1) ES320729A1 (enExample)
FI (1) FI45048C (enExample)
FR (2) FR1469035A (enExample)
GB (1) GB1132244A (enExample)
IL (1) IL24797A (enExample)
NL (2) NL6516326A (enExample)
NO (1) NO117424B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH448083A (de) * 1963-05-04 1967-12-15 Ciba Geigy Verwendung von neuen Hydroxyaryl-pyrimidinen bei Verfahren zum Schützen von nicht-textilen organischen Materialien
CA2406562C (en) * 2000-05-08 2009-09-15 Janssen Pharmaceutica N.V. Hiv replication inhibiting pyrimidines and triazines
GB0206215D0 (en) * 2002-03-15 2002-05-01 Novartis Ag Organic compounds
GB0305929D0 (en) * 2003-03-14 2003-04-23 Novartis Ag Organic compounds
ATE542801T1 (de) 2003-08-15 2012-02-15 Novartis Ag Zur behandlung von neoplastischen krankheiten, entzündlichen erkrankungen und erkrankungen des immunsystems geeignete 2,4-pyrimidindiamine
CA2626789A1 (en) * 2005-10-21 2007-04-26 Exelixis, Inc. Pyrimidinones as casein kinase ii (ck2) modulators
EA019941B1 (ru) 2006-12-08 2014-07-30 АйАрЭм ЭлЭлСи Соединения и композиции в качестве ингибиторов протеинкиназы
LU92852B1 (en) 2015-10-20 2017-05-02 Athanasios Spathis NURR1:RXR activating compounds for simultaneous treatment of symptoms and pathology of Parkinsons disease

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB971307A (en) * 1961-03-02 1964-09-30 Wellcome Found 5-anilinopyrimidines

Also Published As

Publication number Publication date
GB1132244A (en) 1968-10-30
FI45048B (enExample) 1971-11-30
BR6575691D0 (pt) 1973-09-06
BE673707A (enExample) 1966-04-01
FR1469035A (fr) 1967-02-10
DK117835B (da) 1970-06-08
NL129020C (enExample)
CH451945A (de) 1968-05-15
US3361749A (en) 1968-01-02
FR5213M (enExample) 1967-07-03
NO117424B (enExample) 1969-08-11
FI45048C (fi) 1972-03-10
IL24797A (en) 1969-11-12
ES320729A1 (es) 1966-05-16
AT256854B (de) 1967-09-11
DE1545978A1 (de) 1969-12-11

Similar Documents

Publication Publication Date Title
FI45048B (enExample)
AU442366B2 (enExample)
BE603534A (enExample)
BE483969A (enExample)
BE628611A (enExample)
BE47396A (enExample)
BE642114A (enExample)
BE610935A (enExample)
BE642974A (enExample)
BE642437A (enExample)
BE613833A (enExample)
BE659219A (enExample)
BE642104A (enExample)
BE642735A (enExample)
BE636791A (enExample)
BE518974A (enExample)
BE642654A (enExample)
BE642458A (enExample)
BE627057A (enExample)
BE642770A (enExample)
BE657162A (enExample)
BE627931A (enExample)
BE629793A (enExample)
BE637777A (enExample)
BE642797A (enExample)